- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-250/24: Judgment of the General Court of 30 April 2025 – Serana Europe v EUIPO – Cytogen Produkte für Medizin + Forschung (Lymphogrow) (EU trade mark – Opposition proceedings – Application for EU word mark Lymphogrow – Non-registered earlier signs Lymphogrow – Relative ground for refusal – Use in the course of trade of a sign of more than mere local significance – Article 8(4) of Regulation (EU) 2017/1001)
ECLI:EU:UNKNOWN:62024TA0250
62024TA0250
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2025/3285
(Case T-250/24)
(EU trade mark - Opposition proceedings - Application for EU word mark Lymphogrow - Non-registered earlier signs Lymphogrow - Relative ground for refusal - Use in the course of trade of a sign of more than mere local significance - Article 8(4) of Regulation (EU) 2017/1001)
(C/2025/3285)
Language of the case: German
Parties
Applicant: Serana Europe GmbH (Pessin, Germany) (represented by: T. Bösling and I. George, lawyers)
Defendant: European Union Intellectual Property Office (represented by: D. Stoyanova-Valchanova, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Cytogen Produkte für Medizin + Forschung GmbH (Greven, Germany) (represented by: C. Röhl, J. Haßold and P. Richnow, lawyers)
Re:
By its action under Article 263 TFEU, the applicant seeks the annulment and the alteration of the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 12 March 2024 (Case R 1707/2023-2).
Operative part of the judgment
The Court:
Dismisses the action;
Orders Serana Europe GmbH to bear its own costs and to pay those incurred by CYTOGEN – Produkte für Medizin + Forschung GmbH;
Orders the European Union Intellectual Property Office (EUIPO) to bear its own costs.
—
(1) OJ C C/2024/3801, 24.6.2024.
ELI: http://data.europa.eu/eli/C/2025/3285/oj
ISSN 1977-091X (electronic edition)
—